New drug discovery strategies for rheumatoid arthritis: a niche for nonhuman primate models to address systemic complications in inflammatory arthritis

Bibliography

• Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 2002;4(Suppl 3):S265-72
   PubMedGoogle Scholar
• source: the National Rheumatoid Arthritis Foundation. 2012
   Google Scholar
• Bax M, van Heemst J, Huizinga TW, Genetics of rheumatoid arthritis: what have we learned? Immunogenetics 2011;63(8):459-66
   PubMed Web of Science ®Google Scholar
• Gregersen PK, Lee HS, Batliwalla F, PTPN22: setting thresholds for autoimmunity. Semin Immunol 2006;18(4):214-23
   PubMed Web of Science ®Google Scholar
• van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50(3):709-15
   PubMed Web of Science ®Google Scholar
• van der Helm-van Mil AH, Huizinga TW, de Vries RR, Emerging patterns of risk factor make-up enable subclassification of rheumatoid arthritis. Arthritis Rheum 2007;56(6):1728-35
   PubMed Web of Science ®Google Scholar
• van der Helm-van Mil AH, Huizinga TW. Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Res Ther 2008;10(2):205
   PubMedGoogle Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007;146(6):406-15
   PubMed Web of Science ®Google Scholar
• Rantalaiho V, Korpela M, Hannonen P, The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 2009;60(5):1222-31
   PubMed Web of Science ®Google Scholar
• van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Rheum 2009;61(1):4-12
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Breedveld FC, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69(6):964-75
   PubMed Web of Science ®Google Scholar
• Maggon, Krishnan; Guild (KPG), Knol Publishing. Top Ten/Twenty Best Selling Drugs 2010:World Best Selling Human Medicinal Brands 2010, Top Ten, Top Twenty, First Global Market Report [Internet]. Version 70. Knol. 2011 Nov 10. Available from: http://knol.google.com/k/krishan-maggon/top-ten-twenty-best-selling-drugs-2010/3fy5eowy8suq3/141.
   Google Scholar
• Tang W, Lu Y, Tian QY, The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 2011;332(6028):478-84
   PubMed Web of Science ®Google Scholar
• Wu H, Siegel RM. Medicine. Progranulin resolves inflammation. Science 2011;332(6028):427-8
   PubMed Web of Science ®Google Scholar
• Liu CJ. Progranulin: a promising therapeutic target for rheumatoid arthritis. FEBS Lett 2011;585(23):3675-80
   PubMed Web of Science ®Google Scholar
• Bergman GJ, Hochberg MC, Boers M, Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 2010;39(6):425-41
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27:519-50
   PubMed Web of Science ®Google Scholar
• So A, De Smedt T, Revaz S, A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;9(2):R28
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371(9617):987-97
   PubMed Web of Science ®Google Scholar
• Nakashima Y, Kondo M, Harada H, Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Mod Rheumatol 2010;20(4):343-52
   PubMed Web of Science ®Google Scholar
• Nishimoto N. Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol 2006;18(3):277-81
   PubMed Web of Science ®Google Scholar
• Kremer JM, Bloom BJ, Breedveld FC, The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60(7):1895-905
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M, Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353(11):1114-23
   PubMed Web of Science ®Google Scholar
• Kremer JM, Westhovens R, Leon M, Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349(20):1907-15
   PubMed Web of Science ®Google Scholar
• van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP Antibody, a marker for the early detection of rheumatoid arthritis. Ann NY Acad Sci 2008;1143:268-85
   PubMed Web of Science ®Google Scholar
• van Boekel MA, Vossenaar ER, van den Hoogen FH, Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002;4(2):87-93
   PubMedGoogle Scholar
• Cohen SB, Emery P, Greenwald MW, Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54(9):2793-806
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann R, Filipowicz-Sosnowska A, The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54(5):1390-400
   PubMed Web of Science ®Google Scholar
• Magnusson M, Brisslert M, Zendjanchi K, Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment. Rheumatology (Oxford) 2010;49(10):1911-19
   PubMed Web of Science ®Google Scholar
• Isaacs JD. The changing face of rheumatoid arthritis: sustained remission for all? Nat Rev Immunol 2010;10(8):605-11
   PubMed Web of Science ®Google Scholar
• van den Broek M, Huizinga TW, Dijkmans BA, Drug-free remission: is it already possible? Curr Opin Rheumatol 2011;23(3):266-72
   PubMed Web of Science ®Google Scholar
• Woodrick RS, Ruderman EM. Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol 2011;7(11):639-52
   PubMed Web of Science ®Google Scholar
• Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 2011;7(7):399-408
   PubMed Web of Science ®Google Scholar
• Gonzalez A, Maradit Kremers H, Crowson CS, The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007;56(11):3583-7
   PubMed Web of Science ®Google Scholar
• Kannan K, Ortmann RA, Kimpel D. Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology 2005;12(3):167-81
   PubMedGoogle Scholar
• Holmdahl R, Bockermann R, Backlund J, The molecular pathogenesis of collagen-induced arthritis in mice–a model for rheumatoid arthritis. Ageing Res Rev 2002;1(1):135-47
   PubMed Web of Science ®Google Scholar
• Keffer J, Probert L, Cazlaris H, Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. Embo J 1991;10(13):4025-31
   PubMed Web of Science ®Google Scholar
• Horai R, Saijo S, Tanioka H, Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000;191(2):313-20
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N. Animal models of arthritis caused by systemic alteration of the immune system. Curr Opin Immunol 2005;17(6):589-94
   PubMed Web of Science ®Google Scholar
• Matsuno H, Yudoh K, Uzuki M, The SCID-HuRAg mouse as a model for rheumatoid arthritis. Mod Rheumatol 2001;11:6-9
   PubMedGoogle Scholar
• Mestas J, Hughes CC. Of Mice and Not Men: differences between mouse and human immunology. J Immunol 2004;172(5):2731-8
   PubMed Web of Science ®Google Scholar
• Adams AB, Williams MA, Jones TR, Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003;111(12):1887-95
   PubMed Web of Science ®Google Scholar
• Sachs DH. Tolerance: of mice and men. J Clin Invest 2003;111(12):1819-21
   PubMed Web of Science ®Google Scholar
• Bakker NP, van Erck MG, Otting N, Resistance to collagen-induced arthritis in a nonhuman primate species maps to the major histocompatibility complex class I region. J Exp Med 1992;175(4):933-7
   PubMed Web of Science ®Google Scholar
• Vierboom MP, Jonker M, Bontrop RE, Modeling human arthritic diseases in nonhuman primates. Arthritis Res Ther 2005;7(4):145-54
   PubMed Web of Science ®Google Scholar
• Vierboom MP, Jonker M, Tak PP, Preclinical models of arthritic disease in non-human primates. Drug Discov Today 2007;12(7-8):327-35
   PubMed Web of Science ®Google Scholar
• Goossens PH, Schouten GJ, 't Hart BA, Feasibility of adenovirus-mediated nonsurgical synovectomy in collagen- induced arthritis-affected rhesus monkeys. Hum Gene Ther 1999;10(7):1139-49
   PubMed Web of Science ®Google Scholar
• Vierboom MP, Zavodny PJ, Chou CC, Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. Arthritis Rheum 2005;52(2):627-36
   PubMed Web of Science ®Google Scholar
• Brok HP, Tekoppele JM, Hakimi J, Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys. Clin Exp Immunol 2001;124(1):134-41
   PubMed Web of Science ®Google Scholar
• Bakker NP, Van Besouw N, Groenestein R, The anti-arthritic and immunosuppressive effects of cyclosporin A on collagen-induced arthritis in the rhesus monkey. Clin Exp Immunol 1993;93(3):318-22
   PubMedGoogle Scholar
• Zheng B, Zhang X, Guo L, IgM plays an important role in induction of collagen-induced arthritis. Clin Exp Immunol 2007;149(3):579-85
   PubMed Web of Science ®Google Scholar
• Vierboom MP, Breedveld E, Kondova I, Collagen-induced arthritis in common marmosets: a new nonhuman primate model for chronic arthritis. Arthritis Res Ther 2010;12(5):R200
   PubMedGoogle Scholar
• Vierboom MP, Breedveld E, Kondova I, The significance of non-human primates as preclinical models of human arthritic disease. Expert Opin Drug Discov 2008;3(3):1-11
   PubMedGoogle Scholar
• Vierboom MPM, Breedveld E, 't Hart BA. Preclinical evaluation of anti-rheumatic drugs in a non-human primate model of arthritic disease. Drug Discov Today 2008;5(2):89-95
   Google Scholar
• Otting N, Heijmans CM, Noort RC, Unparalleled complexity of the MHC class I region in rhesus macaques. Proc Natl Acad Sci USA 2005;102(5):1626-31
   PubMed Web of Science ®Google Scholar
• Avina-Zubieta JA, Choi HK, Sadatsafavi M, Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59(12):1690-7
   PubMed Web of Science ®Google Scholar
• Mendis S, Nordet P, Fernandez-Britto JE, Atherosclerosis in children and young adults: an overview of the world health organization and international society and federation of cardiology study on pathobiological determinants of atherosclerosis in youth study (1985 – 1995). Prev Control 2005;1:3-15
   Google Scholar
• Zieske AW, Malcom GT, Strong JP. Natural history and risk factors of atherosclerosis in children and youth: the PDAY study. Pediatr Pathol Mol Med 2002;21(2):213-37
   PubMedGoogle Scholar
• Berenson GS, Srinivasan SR, Hunter SM, Risk factors in early life as predictors of adult heart disease: the Bogalusa Heart Study. Am J Med Sci 1989;298(3):141-51
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med 1999;340(2):115-26
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105(9):1135-43
   PubMed Web of Science ®Google Scholar
• Boers M, Nurmohamed MT, Doelman CJ, Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62(9):842-5
   PubMed Web of Science ®Google Scholar
• Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum 2009;38(5):372-81
   PubMed Web of Science ®Google Scholar
• Situnayake RD, Kitas G. Dyslipidemia and rheumatoid arthritis. Ann Rheum Dis 1997;56(6):341-2
   PubMed Web of Science ®Google Scholar
• Ansell BJ, Navab M, Watson KE, Anti-inflammatory properties of HDL. Rev Endocr Metab Disord 2004;5(4):351-8
   PubMed Web of Science ®Google Scholar
• Kremer JM, Lawrence DA, Petrillo GF, Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs. Clinical and immune correlates. Arthritis Rheum 1995;38(8):1107-14
   PubMed Web of Science ®Google Scholar
• Geusens P, Wouters C, Nijs J, Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. A 12-month, double-blind, controlled study. Arthritis Rheum 1994;37(6):824-9
   PubMed Web of Science ®Google Scholar
• Iso H, Kobayashi M, Ishihara J, Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation 2006;113(2):195-202
   PubMed Web of Science ®Google Scholar
• Gilroy DW, Lawrence T, Perretti M, Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 2004;3(5):401-16
   PubMed Web of Science ®Google Scholar
• Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol 2010;177(4):1576-91
   PubMed Web of Science ®Google Scholar
• Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8(5):349-61
   PubMed Web of Science ®Google Scholar
• Serhan CN, Hong S, Gronert K, Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002;196(8):1025-37
   PubMed Web of Science ®Google Scholar
• Serhan CN. The resolution of inflammation: the devil in the flask and in the details. Faseb J 2011;25(5):1441-8
   PubMed Web of Science ®Google Scholar
• Albers JJ, Pitman W, Wolfbauer G, Relationship between phospholipid transfer protein activity and HDL level and size among inbred mouse strains. J Lipid Res 1999;40(2):295-301
   PubMed Web of Science ®Google Scholar
• Ishibashi S, Brown MS, Goldstein JL, Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993;92(2):883-93
   PubMed Web of Science ®Google Scholar
• Tangirala RK, Rubin EM, Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res 1995;36(11):2320-8
   PubMed Web of Science ®Google Scholar
• Kowala MC, Recce R, Beyer S, Characterization of atherosclerosis in LDL receptor knockout mice: macrophage accumulation correlates with rapid and sustained expression of aortic MCP-1/JE. Atherosclerosis 2000;149(2):323-30
   PubMed Web of Science ®Google Scholar
• Nikolaisen C, Figenschau Y, Nossent JC. Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality. J Rheumatol 2008;35(3):380-6
   PubMed Web of Science ®Google Scholar
• Han C, Rahman MU, Doyle MK, Association of anemia and physical disability among patients with rheumatoid arthritis. J Rheumatol 2007;34(11):2177-82
   PubMed Web of Science ®Google Scholar
• Vreugdenhil G, Lowenberg B, Van Eijk HG, Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis. Eur J Clin Invest 1992;22(7):488-93
   PubMed Web of Science ®Google Scholar
• Jongen-Lavrencic M, Peeters HR, Backx B, R-h-erythropoietin counteracts the inhibition of in vitro erythropoiesis by tumour necrosis factor alpha in patients with rheumatoid arthritis. Rheumatol Int 1994;14(3):109-13
   PubMed Web of Science ®Google Scholar
• Peeters HR, Jongen-Lavrencic M, Bakker CH, Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures. Rheumatol Int 1999;18(5-6):201-6
   PubMed Web of Science ®Google Scholar
• Nemeth E, Valore EV, Territo M, Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101(7):2461-3
   PubMed Web of Science ®Google Scholar
• Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003;102(3):783-8
   PubMed Web of Science ®Google Scholar
• Peeters HR, Jongen-Lavrencic M, Vreugdenhil G, Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial. Ann Rheum Dis 1996;55(10):739-44
   PubMed Web of Science ®Google Scholar
• Desai S, Myles M, Kaplan M. Getting to the Heart of the Matter: The Need for More Aggressive Management of Cardiovascular Risk Factors in Rheumatoid Arthritis Abstract. ACR; 2011
   Google Scholar
• Yuan XM, Li W. The iron hypothesis of atherosclerosis and its clinical impact. Ann Med 2003;35(8):578-91
   PubMed Web of Science ®Google Scholar
• Kawashiri SY, Kawakami A, Yamasaki S, Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int 2011;31(4):451-6
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010;20(3):222-32
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Suzuki M, Nakamura H, Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011;63(8):1150-8
   PubMed Web of Science ®Google Scholar
• Masuda J, Ross R. Atherogenesis during low level hypercholesterolemia in the nonhuman primate. I. Fatty streak formation. Arteriosclerosis 1990;10(2):164-77
   PubMedGoogle Scholar
• Masuda J, Ross R. Atherogenesis during low level hypercholesterolemia in the nonhuman primate. II. Fatty streak conversion to fibrous plaque. Arteriosclerosis 1990;10(2):178-87
   PubMedGoogle Scholar